Platelet Rich Plasma Injection Into Ovary of Patients With Premature Ovarian Insufficiency

NCT ID: NCT04149028

Last Updated: 2023-02-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-12-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

All encountered cases with POI will be assessed and examined then investigated. Eligible cases will be included in the study

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients will be subjected to injection of autologous PRP inside the ovary about 0.5-1 mml by laparoscopy

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Premature Ovarian Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

All eligible patient will recieve the treatment with PRP
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PRP injection

injection of PRP inside ovary by the assistance of laparoscopy

Group Type EXPERIMENTAL

PRP injection inside the ovary by laparoscoy. The injection volume is 2 ml

Intervention Type PROCEDURE

intraovarian injection of 2 mml of PRP by laparoscopic guide

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PRP injection inside the ovary by laparoscoy. The injection volume is 2 ml

intraovarian injection of 2 mml of PRP by laparoscopic guide

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Premature ovarian insufficiency diagnosed by:
* FSH\> 40 Amenorrhea Menopuasal symptoms Infertility

Exclusion Criteria

* Refusal to participate Secondary POI due chemotherapy, surgery, or radiotherapy Previous treatment with PRP
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tanta University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ayman S Dawood, MD

Lecturer of Obstetrics and gynecology

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Adel Elgergawy

Tanta, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

POFPRP

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effects of UCA-PSCs in Women With POF
NCT05138367 COMPLETED PHASE1